Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Bioventus (NASDAQ:BVS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Insider and Institutional Ownership
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Pulse Biosciences and Bioventus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
| Bioventus | 9.36% | 28.08% | 9.82% |
Risk and Volatility
Pulse Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Valuation and Earnings
This table compares Pulse Biosciences and Bioventus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 10,725.19 | -$72.78 million | ($1.18) | -44.93 |
| Bioventus | $568.09 million | 2.21 | $22.73 million | $0.77 | 19.43 |
Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Pulse Biosciences and Bioventus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 5 | 1 | 2.86 |
| Bioventus | 0 | 0 | 6 | 0 | 3.00 |
Pulse Biosciences currently has a consensus target price of $60.20, suggesting a potential upside of 13.54%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 12.30%. Given Pulse Biosciences’ higher possible upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Bioventus.
Summary
Bioventus beats Pulse Biosciences on 9 of the 15 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
